At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ORIC Oric Pharmaceuticals Inc.
Closed 08-06 16:00:00 EDT
12.93
+0.00
0.00%
盘后12.93
+0.000.00%
19:34 EDT
High13.19Low12.74Vol887.67K
Open13.01D1 Closing12.93Amplitude3.52%
Mkt Cap1.34BTradable Cap1.07BTotal Shares103.52M
T/O11.47MT/O Rate1.07%Tradable Shares82.72M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Evercore ISI Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
TIPRANKS  ·  08-04 23:29
Evercore ISI Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)
TIPRANKS  ·  08-04 21:50
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), ClearPoint Neuro (CLPT) and Keros Therapeutics (KROS)
ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside
TIPRANKS  ·  08-04 21:40
ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside
Oric Pharmaceuticals: Q2 Net Loss Per Share $0.38
THOMSON REUTERS  ·  08-04
Oric Pharmaceuticals: Q2 Net Loss Per Share $0.38
ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate
Benzinga Earnings  ·  08-04
ORIC Pharmaceuticals Q2 EPS $(0.38) Misses $(0.36) Estimate
Oric Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial of Rinzimetostat Plus Darolutamide in mCRPC
Reuters  ·  08-04
Oric Pharmaceuticals Initiates Himalayas-1 Phase 3 Trial of Rinzimetostat Plus Darolutamide in mCRPC
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
GlobeNewswire  ·  08-04
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Oric Pharmaceuticals Expands 2022 Inducement Equity Plan Share Pool by 1,100,000 Shares
Reuters  ·  07-31
Oric Pharmaceuticals Expands 2022 Inducement Equity Plan Share Pool by 1,100,000 Shares
Oric Pharma Director Richard A. Heyman Disposes of 13,100 Common Shares Worth $157,462.00
Reuters  ·  07-29
Oric Pharma Director Richard A. Heyman Disposes of 13,100 Common Shares Worth $157,462.00
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
GlobeNewswire  ·  07-20
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Corrected-oric Pharmaceuticals: ‍entered Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Darolutamide for Himalayas-1 (not 'oric Pharmaceuticals Inc: Proposed Deal For')
THOMSON REUTERS  ·  07-15
Corrected-oric Pharmaceuticals: ‍entered Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Darolutamide for Himalayas-1 (not 'oric Pharmaceuticals Inc: Proposed Deal For')
Oric Pharmaceuticals Signs Trial Collaboration with Bayer for Nubeqa Supply in Phase 3 Prostate Cancer Study
Reuters  ·  07-15
Oric Pharmaceuticals Signs Trial Collaboration with Bayer for Nubeqa Supply in Phase 3 Prostate Cancer Study
Oric® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in Mcrpc Evaluating Rinzimetostat in Combination with Nubeqa® (darolutamide), Supported by Clinical Collaboration with Bayer
THOMSON REUTERS  ·  07-15
Oric® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in Mcrpc Evaluating Rinzimetostat in Combination with Nubeqa® (darolutamide), Supported by Clinical Collaboration with Bayer
Oric Pharmaceuticals Inc: Proposed Deal For
THOMSON REUTERS  ·  07-15
Oric Pharmaceuticals Inc: Proposed Deal For
Oric Pharmaceuticals Director Richard A. Heyman Sells 300 Shares for $3,600
Reuters  ·  07-09
Oric Pharmaceuticals Director Richard A. Heyman Sells 300 Shares for $3,600
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  07-03
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)
TIPRANKS  ·  06-24
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)
Oric Shareholders Approve Equity Plan, Governance Measures
TIPRANKS  ·  06-23
Oric Shareholders Approve Equity Plan, Governance Measures
Oric Pharmaceuticals shareholders approve amended, restated 2020 equity incentive plan
Reuters  ·  06-23
Oric Pharmaceuticals shareholders approve amended, restated 2020 equity incentive plan
Oric Pharmaceuticals Inc : Stifel Resumes Coverage With Buy Rating; Target Price $14
THOMSON REUTERS  ·  06-12
Oric Pharmaceuticals Inc : Stifel Resumes Coverage With Buy Rating; Target Price $14

Introduction

Company Name.
Oric Pharmaceuticals Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Issue price:
--